Literature DB >> 15901923

Clonogenic cell survival assay.

Anupama Munshi1, Marvette Hobbs, Raymond E Meyn.   

Abstract

The clonogenic cell survival assay determines the ability of a cell to proliferate indefinitely, thereby retaining its reproductive ability to form a large colony or a clone. This cell is then said to be clonogenic. A cell survival curve is therefore defined as a relationship between the dose of the agent used to produce an insult and the fraction of cells retaining their ability to reproduce. Although clonogenic cell survival assays were initially described for studying the effects of radiation on cells and have played an essential role in radiobiology, they are now widely used to examine the effects of agents with potential applications in the clinic. These include, in addition to ionizing radiation, chemotherapy agents such as etoposide and cisplatin, antiangiogenic agents such as endostatin and angiostatin, and cytokines and their receptors, either alone or in combination therapy. Survival curves have been generated for many established cell lines growing in culture. One can use cell lines from various origins including humans and rodents; these cells can be neoplastic or normal. Because survival curves have wide application in evaluating the reproductive integrity of different cells, we provide here the steps involved in setting up a typical experiment using an established cell line in culture.

Entities:  

Mesh:

Year:  2005        PMID: 15901923     DOI: 10.1385/1-59259-869-2:021

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  88 in total

1.  Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.

Authors:  Hong Zhou; Yuying Liu; Lawrence H Cheung; Sehoon Kim; Weihe Zhang; Khalid A Mohamedali; Preetha Anand; Walter N Hittelman; Bharat B Aggarwal; Michael G Rosenblum
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Dying tumor cells stimulate proliferation of living tumor cells via caspase-dependent protein kinase Cδ activation in pancreatic ductal adenocarcinoma.

Authors:  Jin Cheng; Ling Tian; Jingjing Ma; Yanping Gong; Zhengxiang Zhang; Zhiwei Chen; Bing Xu; Hui Xiong; Chuanyuan Li; Qian Huang
Journal:  Mol Oncol       Date:  2014-08-07       Impact factor: 6.603

3.  C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression.

Authors:  Vikas Bhardwaj; Yanai Zhan; Maria Angelica Cortez; Kie Kian Ang; David Molkentine; Anupama Munshi; Uma Raju; Ritsuko Komaki; John V Heymach; James Welsh
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

4.  Nanoparticle-Mediated X-Ray Radiation Enhancement for Cancer Therapy.

Authors:  Autumn D Paro; Ilanchezhian Shanmugam; Anne L van de Ven
Journal:  Methods Mol Biol       Date:  2017

5.  Clonogenic Assays to Detect Cell Fate in Mitotic Catastrophe.

Authors:  José Manuel Bravo-San Pedro; Oliver Kepp; Allan Sauvat; Santiago Rello-Varona; Guido Kroemer; Laura Senovilla
Journal:  Methods Mol Biol       Date:  2021

6.  Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas.

Authors:  Amanda R King; Christopher D Corso; Evan M Chen; Eric Song; Paul Bongiorni; Zhe Chen; Ranjini K Sundaram; Ranjit S Bindra; W Mark Saltzman
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

7.  Pharmacological Ascorbate as an Adjuvant for Enhancing Radiation-Chemotherapy Responses in Gastric Adenocarcinoma.

Authors:  Brianne R O'Leary; Frederick K Houwen; Chase L Johnson; Bryan G Allen; James J Mezhir; Daniel J Berg; Joseph J Cullen; Douglas R Spitz
Journal:  Radiat Res       Date:  2018-03-16       Impact factor: 2.841

8.  High-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell.

Authors:  Young-Joo Shin; Mi-Sook Kim; Moon-Sun Kim; Joonseok Lee; Miae Kang; Jae-Hoon Jeong
Journal:  Cancer Biol Ther       Date:  2012-12-19       Impact factor: 4.742

9.  6-Methoxyquinoline complexes as lung carcinoma agents: induction of oxidative damage on A549 monolayer and multicellular spheroid model.

Authors:  J F Cadavid-Vargas; C Villa-Pérez; M C Ruiz; I E León; G C Valencia-Uribe; D B Soria; S B Etcheverry; A L Di Virgilio
Journal:  J Biol Inorg Chem       Date:  2019-01-30       Impact factor: 3.358

10.  Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery.

Authors:  Xi Tian; Haydee Lara; Kyle T Wagner; Srinivas Saripalli; Syed Nabeel Hyder; Michael Foote; Manish Sethi; Edina Wang; Joseph M Caster; Longzhen Zhang; Andrew Z Wang
Journal:  Nanoscale       Date:  2015-11-17       Impact factor: 7.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.